Immunogenicity of pluripotent stem cells and their derivatives.
The ability of pluripotent stem cells to self-renew and differentiate into all somatic cell types brings great prospects to regenerative medicine and human health. However, before clinical applications, much translational research is necessary to ensure that their therapeutic progenies are functional and nontumorigenic, that they are stable and do not dedifferentiate, and that they do not elicit immune responses that could threaten their survival in vivo. For this, an in-depth understanding of their biology, genetic, and epigenetic make-up and of their antigenic repertoire is critical for predicting their immunogenicity and for developing strategies needed to assure successful long-term engraftment. Recently, the expectation that reprogrammed somatic cells would provide an autologous cell therapy for personalized medicine has been questioned. Induced pluripotent stem cells display several genetic and epigenetic abnormalities that could promote tumorigenicity and immunogenicity in vivo. Understanding the persistence and effects of these abnormalities in induced pluripotent stem cell derivatives is critical to allow clinicians to predict graft fate after transplantation, and to take requisite measures to prevent immune rejection. With clinical trials of pluripotent stem cell therapy on the horizon, the importance of understanding immunologic barriers and devising safe, effective strategies to bypass them is further underscored. This approach to overcome immunologic barriers to stem cell therapy can take advantage of the validated knowledge acquired from decades of hematopoietic stem cell transplantation.
Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305-5454, USA.
Patricia E
PE
de Almeida
Julia D
JD
Ransohoff
Abu
A
Nahid
Joseph C
JC
Wu
D000017:ABO Blood-Group System / Q000276:immunology; D056704:Adaptive Immunity; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D002470:Cell Survival; D044127:Epigenesis, Genetic; D005786:Gene Expression Regulation; D006084:Graft Rejection / Q000276:immunology*; D006648:Histocompatibility; D006801:Humans; D007113:Immunity, Innate; D057026:Induced Pluripotent Stem Cells / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D054340:Receptors, KIR / Q000276:immunology; D012038:Regeneration; D044968:Regenerative Medicine / Q000379:methods*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D023001:Transplantation Tolerance; D016896:Treatment Outcome
D000017:ABO Blood-Group System; D015415:Biomarkers; D015778:Minor Histocompatibility Antigens; D054340:Receptors, KIR